Gloucester Pharmaceuticals, Inc.

One Broadway 14th Floor,
Cambridge, Massachusetts 02142
United States,
(617) 583-1300

Gloucester develops cancer therapies including Istodax, which was approved by the Food and Drug Administration last month for treatment of cutaneous T-cell lymphoma patients who have had a least one prior systemic therapy. The treatment also has orphan drug designation for treatment of non-Hodgkin's T-cell lymphomas including CTCL and peripheral T-cell lymphoma, as well as fast-track status for PTCL.

Gloucester Pharmaceuticals was acquired by Celgene on December 07, 2009.

Join Mergr to view all 111 acquisitions of life science companies in 2009, including 13 acquisitions by private equity firms, and 98 by strategics.

Out of 60 sectors in the Mergr database, life science ranked 6 in number of deals in 2009. The largest life science acquisition in 2009 was Wyeth - which was acquired by Pfizer for $68.0B.

Join Mergr to view this profile - and discover more life science acquisitions of companies like Gloucester Pharmaceuticals.

What's Mergr?

Mergr, the Easiest-to-Use PE and M&A DB

Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
  • 3.4K Private Equity Firms
  • 120K M&A Transactions
  • 129K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 2.8K M&A Advisors
    (Investment Banks and Law Firms)
  • 35K M&A Contacts
    (PE and M&A Advisors)

Ready to try?

Join FREE for 1 Week

No obligation. Cancel anytime.